Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) were adenovirally engineered to secrete interleukin-12 (AdIL-12-MSCs) and evaluated for their anticarcinogenesis efficacy against three kinds of unestablished tumor models including B16 melanoma, LLC Lewis lung cancer and HCC hepatoma. Injection of AdIL-12-MSCs into protected mice before tumor inoculation prevented all of 12 mice in B16 preventive groups, 10 out of 12 in LLC lung cancer model and 11 out of 12 mice in HCC hepatoma model from developing tumors, whereas the control groups pre-receiving PBS were validated for 100% carcinogenesis; the tumor formation rates in free-AdIL-12 and vacant MSC groups were unveiled between approximately 83 and 100% even with plentiful angiogenesis and newborn lymphatic vessels, as well as distant metastases. As a novel approach, AdIL-12-MSC has revealed expected preventive effects on carcinogenesis (P<0.01) with low-toxic, broad-spectrum and long-range superiorities. In conclusion, our data indicate that AdIL-12-MSC possess the potential for tropism to preclinical tumor lesions and deprives surviving or hibernating tumor cells, which have escaped from conventional treatments, of revival and recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recombinant IL-12 administration induces tumor regression in association with IFN- gamma production.
Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1697 · Cited by 780
Adult human mesenchymal stem cell as a target for neoplastic transformation
Serakinci, N., Guldberg, P., Burns, J. S., Abdallah, B., Schrødder, H., Jensen, T., & Kassem, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207651 · Cited by 350
Clinical Trials: IL-12 Deaths: Explanation and a Puzzle
Cohen, J. (1995) · Science · doi:10.1126/science.270.5238.908a · Cited by 332
Hung, S.-C., Deng, W.-P., Yang, W. K., Liu, R.-S., Lee, C.-C., Su, T.-C., Lin, R.-J., Yang, D.-M., Chang, C.-W., Chen, W.-H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0876 · Cited by 268
Meyskens, F. L., Surwit, E., Moon, T. E., Childers, J. M., Davis, J. R., Dorr, R. T., Johnson, C. S., & Alberts, D. S. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.539 · Cited by 263
Cited by
Cartilage engineering: a crucial combination of cells, biomaterials and biofactors
Vinatier, C., Mrugala, D., Jorgensen, C., Guicheux, J., & Noël, D. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.02.005 · Cited by 481
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417
“Theoretically, future cell therapies using allogenic MSCs could be used in patients without the use of prior immunomodulation (25).”
BackgroundMesenchymal stem cells: innovative therapeutic tools for rheumatic diseases
Djouad, F., Bouffi, C., Ghannam, S., Noël, D., & Jorgensen, C. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.104 · Cited by 316
Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit?
Lazennec, G., & Jorgensen, C. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1006 · Cited by 255
Adipose-Derived Stem Cells in Tissue Regeneration: A Review
Zuk, P. (2013) · ISRN Stem Cells · doi:10.1155/2013/713959 · Cited by 185
Metadata
- Authors
- Chen, X.-C., Wang, R., Zhao, X., Wei, Y.-Q., Hu, M., Wang, Y.-S., Zhang, X.-W., Zhang, R., Zhang, L., Yao, B., Wang, L., Jia, Y.-Q., Zeng, T.-T., Yang, J.-L., Tian, L., Kan, B., Lin, X.-J., Lei, S., Deng, H.-X., Wen, Y.-J., Mao, Y.-Q., & Li, J.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08-18
- Volume
- 27
- Issue
- 12
- Pages
- 2434-2441
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2128909961
- Cited by
- 79
- References
- 5
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.